MLH1 and malignant colon neoplasm: For colon cancer this was 86% [80%–92%] in path_MLH1, 89% [82%–96%] in path_MSH2 and 85% [67%–100%] in path_MSH6 carriers and for endometrial cancer: 93% [88%–99%], 91% [85%–98%] and 89% [75%–100%], respectively.